READ MORE: Why the new endometriosis guidelines frustrate advocates, doctors Her doctor suggested a GLP-1, especially since her insulin-resistant PMOS contributed to her inability to lose weight

Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
This article will use the terms male, female, or both to refer to sex assigned at birth
CT, P = 0.001), and fatigue severity (LC vs
Prevalence and risk factors for secondary hyperparathyroidism (SHPT) in patients undergoing bariatric surgery